At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ATHE Alterity Therapeutics Limited
Pre-Market Trading 12-24 07:24:01 EST
2.40
+0.20
+9.09%
盘前2.36
-0.04-1.67%
06:33 EST
High2.47
Low2.20
Vol62.09K
Open2.21
D1 Closing2.20
Amplitude12.20%
Mkt Cap21.28M
Tradable Cap18.91M
Total Shares8.87M
T/O146.58K
T/O Rate0.79%
Tradable Shares7.88M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Alterity Therapeutics Initiated at Buy by Maxim Group
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.